Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: A systematic review and meta-analysis

---

作者

Carlos Taxonera¹ , David Olivares¹

1. Hospital Clinico San Carlos, Madrid, Spain

会议/活动

Digestive Disease Week 2023, May 2023 (Chicago, United States)

海报摘要

A systematic search was conducted in electronic databases for observational studies evaluating ustekinumab for UC. Of 254 citations, 19 studies were included with 3786 patients. Clinical remission was achieved in 45.4% of patients at week 8, 43.8% at weeks 12 to 16, 44.6% at month 6, and 50.6% at month 12. Corticosteroid-free remission was achieved in 18.7%, 36.8%, 34.5%, and 39% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Endoscopic improvement was achieved in 29.9%, 24.3%, and 58.2% of patients at weeks 12 to 16, month 6, and month 12, respectively. The IRs of colectomy, AE, serious AE, and serious infections were 4.8, 7.9, 0.8 and 0.3 per 100 PY, respectively. The results of this meta-analysis of observational studies confirm the effectiveness of ustekinumab in UC. The acceptable safety data support the positive long-term benefit-risk profile of ustekinumab for UC.

关键词

Ustekinumab, Ulcerative colitis, Real-world evidence, Systematic review, Meta-analysis

研究领域

Medicine

参考文献

暂无数据

基金

暂无数据

补充材料

暂无数据

附加信息

利益冲突

No competing interests were disclosed.

数据可用性声明

The datasets generated during and / or analyzed during the current study are available from the corresponding author on reasonable request.

知识共享许可协议

Copyright © 2023 Taxonera et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.